Dogwood Therapeutics, Inc. (Nasdaq: DWTX) reported financial results for the first quarter ended March 31, 2026, as the biopharmaceutical company advances its pipeline of first-in-class non-opioid pain treatments toward key clinical milestones. The company is developing Halneuron, a NaV 1.7 inhibitor for chemotherapy-induced neuropathic pain (CINP), and SP16, a novel LRP1 agonist for chemotherapy-induced peripheral neuropathy (CIPPN).
CEO Greg Duncan noted a strong operational start to 2026, driven by pipeline progress. The company has enrolled 164 patients in its Halneuron Phase 2b CINP study, with top-line results expected in fall 2026. Halneuron has received Fast Track designation from the FDA. Separately, SP16 received IND approval from the FDA, and its Phase 1b CIPPN trial, fully funded by the National Cancer Institute, will begin enrolling in mid-2026 at the University of Virginia.
In January 2026, Dogwood completed a financing of up to $26.9 million, with gross proceeds of $12.5 million received, to support Halneuron through Phase 2b development. The company ended the quarter with $13.2 million in cash, providing operational runway into the fourth quarter of 2026.
For the first quarter, research and development expenses were $2.7 million, up from $2.4 million in Q1 2025, driven by increased drug development costs for Halneuron and higher personnel costs. General and administrative expenses rose to $2.4 million from $2.0 million, primarily due to increased salaries. Net loss attributable to common stockholders was $5.0 million, or $0.15 per share, compared to a net loss of $12.2 million, or $8.45 per share, in the prior-year period, reflecting the absence of a loss on debt conversion.
Dogwood's pipeline addresses a significant unmet need in pain management. Halneuron is a non-opioid, voltage-gated sodium channel modulator (NaV 1.7) that has demonstrated pain reduction in clinical studies. SP16 acts as an LRP1 agonist, providing anti-inflammatory and tissue-repair effects via reductions in IL-6, IL-8, IL1B and TNF-alpha, and increases in pAKT and pERK. Both candidates target neuropathic pain associated with chemotherapy, a condition affecting many cancer survivors.
The company also noted that it executed a global development license for its legacy combination antiviral assets. Dogwood's largest shareholder is a member of CK Life Sciences Int’l., (Holdings) Inc., listed on the Hong Kong Stock Exchange. For more information, visit www.dwtx.com.
Forward-looking statements in the press release highlight risks inherent in clinical development, including the timing and results of current and future studies. The company undertakes no duty to update such information except as required by law.
